Cardiol Therapeutics Inc is conducting clinical trials on its pure cannabidiol formulation, CardiolRx, to treat inflammatory heart disease


Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular disease (“ CVD”).

The Company’s lead product candidate, CardiolRx™, is a pharmaceutically produced oral formulation of cannabidiol that is in clinical development for use in cardiovascular medicine. CardiolRx™ is currently being evaluated in a Phase II/III multinational, randomized, double-blind, placebo-controlled study (the LANCER trial). LANCER is designed to evaluate the efficacy and safety of CardiolRx™ as a cardioprotective therapy to reduce major cardiovascular and respiratory events in patients hospitalized with COVID-19 who have a history or risk factors for CVD, and to study the influence CardiolRx™ has on key biomarkers associated with heart disease.

Cardiol also received IND clearance from the FDA to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two orphan drug indications: (i) a multinational, randomized, phase II trial in double-blind, placebo-controlled treatment in myocarditis, an important cause of acute and fulminant heart failure in young adults and the leading cause of sudden cardiac death in people under 35; and (ii) a phase II multicenter open-label pilot study in recurrent pericarditis (inflammation of the pericardium), which is associated with symptoms such as debilitating chest pain, shortness of breath and fatigue, and results in physical limitations, quality reduced life, emergency room visits and hospitalizations.

Additionally, Cardiol is developing a subcutaneous formulation of cannabidiol targeting the inflammation and fibrosis associated with the development and progression of heart failure – a chronic disease estimated to affect 64 million people worldwide and is one of of the leading causes of death and hospitalization, with associated annual healthcare costs in the United States alone exceeding $30 billion.


Comments are closed.